Patents by Inventor Michael Kyba

Michael Kyba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911367
    Abstract: A method for treating a cancer involving one or more translocations generating an oncogenic fusion transcription factor that requires p300/CBP for activity in an animal, comprising administering a compound of formula (I): or a pharmaceutically acceptable salt thereof to the animal.
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: February 27, 2024
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Michael Kyba, Darko Bosnakovski
  • Publication number: 20220288032
    Abstract: A method for treating a cancer involving one or more translocations generating an oncogenic fusion transcription factor that requires p300/CBP for activity in an animal, comprising administering a compound of formula (I): or a pharmaceutically acceptable salt thereof to the animal.
    Type: Application
    Filed: March 10, 2022
    Publication date: September 15, 2022
    Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Michael Kyba, Darko Bosnakovski
  • Patent number: 11306287
    Abstract: Compositions and methods of the invention are directed to the formation and use of teratoma-derived skeletal muscle stem cells. In one embodiment, the teratoma-derived skeletal muscle stem cells improve muscle contractile force (definition “functional”) when administered to a patient in need thereof.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: April 19, 2022
    Assignee: Regents of the University of Minnesota
    Inventors: Michael Kyba, Sun Kin Sunny Chan, Robert W. Arpke
  • Patent number: 9850497
    Abstract: Provided herein is a general method of correcting a gene, for example a gene with many known mutations, such as a gene with mutations in many different exons which could vary from subject to subject (e.g., patient), as well as a set of tools (TALENs and gene targeting vectors) to accomplish such method.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: December 26, 2017
    Assignee: Regents of the University of Minnesota
    Inventors: Rita Perlingeiro, Michael Kyba, Fabrizio Rinaldi, Daniel F. Voytas
  • Publication number: 20150125429
    Abstract: Provided herein is a general method of correcting a gene, for example a gene with many known mutations, such as a gene with mutations in many different exons which could vary from subject to subject (e.g., patient), as well as a set of tools (TALENs and gene targeting vectors) to accomplish such method.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 7, 2015
    Inventors: Rita Perlingeiro, Michael Kyba, Fabrizio Rinaldi, Daniel F. Voytas
  • Publication number: 20070243608
    Abstract: Platelets are produced in a bioreactor in which hematopoietic stem cells (HSCs) are cultured to produce megakaryoctye progenitors, megakaryocytes, and platelets. The HSCs are stably genetically engineered to express HoxA2 or HoxB2 which induces HSC proliferation and promotes generation of megakaryocytes.
    Type: Application
    Filed: April 14, 2006
    Publication date: October 18, 2007
    Inventors: Michael Kyba, Michelina Iacovino
  • Publication number: 20030228293
    Abstract: A method of correcting of treating a genetic disorder by combining therapeutic cloning and gene therapy.
    Type: Application
    Filed: March 7, 2003
    Publication date: December 11, 2003
    Applicants: Whitehead Institute for Biomedical Research, The General Hospital Corporation
    Inventors: William Rideout, Konrad Hochedlinger, Michael Kyba, Rita Perlingeiro, George Q. Daley, Rudolf Jaenisch